Confirm diagnosis of anti-NMDAR encephalitis. May be used in monitoring treatment response in individuals who are antibody positive.
Semi-Quantitative Indirect Fluorescent Antibody
New York DOH Approval Status
Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Contaminated, hemolyzed, or severely lipemic specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Effective May 21, 2012
Anti-NMDA receptor IgG antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
If NMDA CSF antibody IgG is positive, then an NMDA CSF antibody IgG titer is reported. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|2005165||N-methyl-D-Aspartate Receptor Ab, CSF||80220-7|
- Anti-NMDA CSF
- Glutamate Receptor Antibodies
- N-Methyl D-Aspartate Ab CSF
- NMDA R
- NMDA Receptor Ab CSF